Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Sagimet Biosciences
company
About
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
- 11 - 50
Details
- Last Funding Type
- Series E
- Last Funding Money Raised
- $7M
- Industries
- Biopharma,Biotechnology,Therapeutics
- Founded date
- Mar 1, 2007
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASN inhibitors.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$7M
Sagimet Biosciences has raised a total of
$7M
in funding over 2 rounds. Their latest funding was raised on
Aug 5, 2019 from a Series E round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 5, 2019 | Series E | $7M | 1 | — | — | Detail |
Investments
Number of Investments
Number of Lead Investments
1
0
Sagimet Biosciences has made 1 investments. Their most recent investment was on
Apr 3, 2020, when 98point6 raised $43M.
Investors
Number of Lead Investors
Number of Investors
—
1
Sagimet Biosciences is funded by 1 investors.
Qianhai Ark
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series E |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
